The fungal lactone oxacyclododecindione is a potential new therapeutic substance in the treatment of lupus-associated kidney disease.

doi:10.1038/ki.2014.109

Paper

The fungal lactone oxacyclododecindione is a potential new therapeutic substance in the treatment of lupus-associated kidney disease.

Published Oct 1, 2014 · Jenny Henke, G. Erkel, C. Brochhausen

Kidney international

Q1 SJR score

14

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Study Snapshot

Oxacyclododecindione (Oxa) shows potential as a new anti-inflammatory compound for treating lupus-associated kidney disease by reducing inflammation and immune cell infiltration.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

The fungal lactone oxacyclododecindione is a potential new therapeutic substance in the treatment of lupus-associated kidney disease.

Sign up to use Study Snapshot

References

Citations